Group classification of medication using and validity of ankylosing spondylitis diagnosis

Pharmacol Res. 2022 Nov:185:106465. doi: 10.1016/j.phrs.2022.106465. Epub 2022 Sep 24.

Authors

Hui-Chin Chang¹, Shuo-Yan Gau²

Affiliations

¹ School of Medicine, Chung Shan Medical University, Taichung, Taiwan; Library, Chung Shan Medical University Hospital, Taichung, Taiwan; Evidence-based Medicine Center, Chung Shan Medical University Hospital, Taichung, Taiwan.
² School of Medicine, Chung Shan Medical University, Taichung, Taiwan. Electronic address: [email protected].

PMID: 36162601
DOI: 10.1016/j.phrs.2022.106465

No abstract available

Keywords: Ankylosing spondylitis; Clalit Health Services; Dementia; TNF inhibitors.

Publication types

Letter

MeSH terms

Antirheumatic Agents* / therapeutic use
Humans
Severity of Illness Index
Spondylitis, Ankylosing* / diagnosis
Spondylitis, Ankylosing* / drug therapy
Tumor Necrosis Factor-alpha

Substances

Antirheumatic Agents
Tumor Necrosis Factor-alpha